Peptide analogues of glucagon and GLP1

摘要

Peptide analogs of glucagon and peptide analogs of GLP1 are provided herein. Also provided herein are pharmaceutical compositions comprising the analogs, and methods of using the analogs for the treatment and/or prevention of conditions such as obesity and diabetes.

主权项

1. An analogue of glucagon which is:
a compound comprising the amino acid sequence represented by formula (I)
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Xaa10-Ser-Xaa12-Xaa13-Leu-Xaa15-Xaa16-Xaa17-Xaa18-Ala-Xaa20-Xaa21-Phe-Xaa23-Xaa24-Trp-Leu-Leu-Asn-Xaa29-V   (I) wherein V is selected from the group consisting of His (SEQ ID NO: 716), His-NH2 (SEQ ID NO: 717), His-His (SEQ ID NO: 718), His-His-NH2 (SEQ ID NO: 719), Gly-His (SEQ ID NO: 720), Gly-His-NH2 (SEQ ID NO: 721), Lys-His (SEQ ID NO: 722), Lys-His-NH2 (SEQ ID NO: 723), Gly-His-His (SEQ ID NO: 724), Gly-His-His-NH2 (SEQ ID NO: 725), His-His-His (SEQ ID NO: 726) and His-His-His-NH2 (SEQ ID NO: 727);
Xaa10 is selected from the group consisting of Tyr and Leu;Xaa12 is selected from the group consisting of Lys, His and Arg;Xaa13 is selected from the group consisting of Tyr, Gln and His;Xaa15 is selected from the group consisting of Asp and Glu;Xaa16 is selected from the group consisting of Glu, Gln and Ser;Xaa17 is selected from the group consisting of Arg, His and Lys;Xaa18 is selected from the group consisting of Arg and Lys;Xaa20 is selected from the group consisting of His and Gln;Xaa21 is selected from the group consisting of Glu, His and Asp;Xaa23 is selected from the group consisting of Be and Val;Xaa24 is selected from the group consisting of Gln and Glu; andXaa29 is selected from the group consisting of Thr and Gly; and wherein —NH2 represents a C-terminal amide group; or a derivative of the compound; or a salt of the compound or the derivative.